[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.205.109.152. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
April 4, 2001

Lipid-Lowering Therapy in Acute Coronary Syndromes

Author Affiliations

Author Affiliation: Department of Nutrition, Harvard School of Public Health, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

JAMA. 2001;285(13):1758-1760. doi:10.1001/jama.285.13.1758

In the unstable clinical state after an acute coronary disease event, patients experience a high rate of serious complications including death, myocardial infarction (MI), and progressively recurring unstable angina requiring intervention.1 The incidence rate sharply declines after 1 month, and then gradually diminishes so that after about 6 months, the incidence of coronary death and MI is fairly constant for the next several years, reflecting a stabilization of the clinical coronary disease. Many successful clinical strategies—including antithrombotic therapy, β-adrenergic blockade, thrombolysis, and angiotensin-converting enzyme inhibition—have been directed toward reducing the high early event rate after onset of acute coronary syndrome.1 Nonetheless, the incidence of serious complications remains high.

×